1-Simforoush N, Nouralizadeh A, Soltani MH, Nafar M. Iranian Text book of urology. 2nd ed. Vol (2). Tehran: Teimourzadeh; 2013. p. 415-49.
2-Ghafoor A, Jemal A, Cokkinides V, Cardinez C, Murray T, Samuels A, et al. Cancer statistics for African Americans. CA Cancer J Clin. 2002;52(6):326-41.
3-Roshandel G, Ghanbari-Motlagh A, Partovipour E, Salavati F, Hasanpour-Heidari S, Mohammadi G, Khoshaabi M, Sadjadi A, Davanlou M, Tavangar SM, Abadi H. Cancer incidence in Iran in 2014: results of the Iranian National Population-based Cancer Registry. Cancer epidemiology. 2019 Aug 1;61:50-8.
4-Sadjadi A, Nooraie M, Ghorbani A, Alimohammadian M, Zahedi MJ, DarvishMoghadam S, et al. The incidence of prostate cancer in Iran: results of a population-based cancer registry. Arch Iran Med. 2007;10(4):481-5.
5-Malekzadeh R. Incidences of differnet cancers in Iran. The 16th International Congress of Geographic. Medicine Shiraz University of Medical Sciences, Shiraz, Iran. 2003;1(4).
6-Hosseini M, Jahani Y, Mahmoodi M, Eshraghian MR, Yahyapour Y, Keshtkar AA. The assessment of risk factors for prostate cancer in Mazandaran province, Iran. J Gorgan Uni Med Sci. 2008;10(3):58-64.
7-Brawer MK, Peehl DM, Stamey TA, Bostwick DG. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 1985;45(8):3663-7.
8-O’Malley FP, Grignon DJ, Shum DT. Usefulness of immunoperoxidase staining with high-molecular-weight cytokeratin in the differential diagnosis of small-acinar lesions of the prostate gland. Virchows Arch A Pathol Anat Histopathol. 1990;417(3):191-6.
9-Jacobsen SJ, Katusic SK, Bergstralh EJ, Oesterling JE, Ohrt D, Klee GG, et al. Incidence of prostate cancer diagnosis in the eras before and after serum prostate-specific antigen testing. JAMA. 1995;274(18):1445-9
10-Shah RB, Zhou M, LeBlanc M, Snyder M, Rubin MA. Comparison of the basal cell- specific markers, 34betaE12 and p63, in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26(9):1161-8.
11-Gaudin PB, Reuter VE. Benign mimics of prostatic adenocarcinoma on needle biopsy. Anat Pathol 1997;2:111-34.
12-Ho ME, Quek SI, True LD, Morrissey C, Corey E, Vessella RL, Dumpit R, Nelson PS, Maresh EL, Mah V, Alavi M. Prostate cancer cell phenotypes based on AGR2 and CD10 expression. Modern Pathology. 2013 Jun;26(6):849.
13-Saranya D. Analysis of Immunohistochemical Expression of CD10 in the Lesions of Prostate (Doctoral dissertation, Chengalpattu Medical College, Chengalpattu).
14-Freedland SJ, Seligson DB, Liu AY, Pantuck AJ, Paik SH, Horvath S, Wieder JA, Zisman A, Nguyen D, Tso CL, Palotie AV. Loss of CD10 (neutral endopeptidase) is a frequent and early event in human prostate cancer. The Prostate. 2003 Apr 1;55(1):71-80.
15-Saranya D. Analysis of immunohistochemical expression of CD10 in the malignant lesions of prostate. IOSR-J of Dental and Med Sci. 2017;16:78-82.
16-Era M, True L, Siegel A, Porter M, Sherertz T, Liu A. Differential expression of CD10 in prostate cancer and its clinical implication. BMC Urology. 2007;1471 -90.
17-Fleischmann A, Schlimm T, Huland H, Kollermann J, Simon P, Mirlacher M et al. Distinct subcellular expression patterns of neutral endopeptidase in prostate cancer predict diverging clinical courses in surgically treated patients. Clinical cancer research. 2008;14:7838- 42.
18-Kaur M, Gupta R, Pant L, Singh S. CD10 expression pattern in prostatic adenocarcinoma: Elucidation of differences between Gleason's grades. The Malaysian journal of pathology. 2018 Apr 1;40(1):57-60.
)